Muhammad Ahmad

Muhammad Ahmad

Auto-generated profile, based on publicly available information

Muhammad Ahmad

Sharif Medical and Dental College, Lahore, Pakistan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
RPRavi Kumar Pandey
Ravi Kumar Pandey
MIMaryam Imran
Maryam Imran
IMIshba Manal
Ishba Manal
MAMuhammad Ahmad
Muhammad Ahmad
ANAliya Noor
Aliya Noor
ARAli Rohan
Ali Rohan
Background and Aim: Multiple pharmacologic therapies reduce chronic kidney disease (CKD) progression in patients with diabetes; however, the absence of head‐to‐head trials and heterogeneity across studies limits the interpretation of indirect comparisons. We evaluated class‐level treatment effects within a predominantly placebo‐centred evidence network. Methods: We conducted a systematic review and class‐level frequentist random‐effects network meta‐analysis of randomised controlled trials evaluating major pharmacologic therapy classes for CKD progression in patients with diabetes. The primary outcome was CKD progression, defined according to the principal composite kidney endpoint reported in each trial. Exploratory analyses evaluated albuminuria reduction and trial‐level surrogate associations between albuminuria and clinical kidney outcomes. Results: Nine trials involving 37,749 participants were included. The evidence network was star‐shaped with placebo as the central comparator. All therapeutic classes were associated with reduced CKD progression compared with placebo. Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) demonstrated the most precise estimate (HR 0.66, 95% CI 0.60–0.74) and were supported by high‐confidence evidence. Confidence in placebo‐referenced estimates for other therapeutic classes ranged from moderate to low because of indirectness, limited trial numbers and differences in study design and patient populations. Findings were generally consistent across sensitivity analyses. No significant association was observed between treatment‐induced albuminuria reduction and clinical kidney outcomes ( R 2 = 0.007), although interpretation was limited by ecological bias and the small number of included studies. Conclusions: Multiple pharmacologic classes were associated with reduced CKD progression compared with placebo in patients with diabetes. Among placebo‐referenced comparisons, the most consistent and highest‐confidence estimates were observed for SGLT2i. However, the predominantly placebo‐centred network, absence of direct active‐comparator trials and important transitivity concerns limit inference regarding comparative efficacy among therapies. Findings should therefore be interpreted as placebo‐referenced class‐level treatment effects rather than evidence of comparative superiority. Direct comparative effectiveness and combination‐therapy trials are needed to define optimal treatment strategies.

13 July 2026 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Open access
RPRavi Pandey
Ravi Pandey
MAMuhammad Ahmad
Muhammad Ahmad
ARAli Rohan
Ali Rohan
INIqra Nurie
Iqra Nurie
SSShano Sherani
Shano Sherani
ASAimen Shafiq
Aimen Shafiq
BackgroundAldosterone excess contributes to uncontrolled and resistant hypertension, making aldosterone synthase inhibition a promising therapeutic strategy. Recent randomized trials have evaluated the selective aldosterone synthase inhibitors Lorundrostat and Baxdrostat; however, their efficacy and safety have not been comprehensively synthesized.MethodsPubMed, Embase, and Cochrane CENTRAL were searched from inception through April 2026 for randomized controlled trials evaluating Lorundrostat or Baxdrostat in adults with uncontrolled or resistant hypertension. The primary efficacy outcome was placebo-adjusted change in systolic blood pressure (SBP). Safety outcomes included hyperkalemia, treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs). Drug-specific pooled analyses were performed using random-effects models.ResultsThree randomized trials of Lorundrostat (n=1,568) demonstrated a significant reduction in SBP compared with placebo (mean difference [MD], -7.51 mmHg; 95% CI, -10.30 to -4.71; I2 = 0%). Lorundrostat increased the risks of hyperkalemia (RR, 8.06; 95% CI, 2.92-22.27) and TEAEs (RR, 1.45; 95% CI, 1.27-1.66), without a significant increase in SAEs. Three placebo-controlled Baxdrostat trials (n = 1,483) also demonstrated significant reductions in office SBP (MD, -8.63 mmHg; 95% CI, -11.30 to -5.96; I2 = 0%). Baxdrostat increased the risk of hyperkalemia (RR, 3.81; 95% CI, 1.82-7.97) but was not associated with significant increases in TEAEs or SAEs.ConclusionsSelective aldosterone synthase inhibition with Lorundrostat and Baxdrostat produced clinically meaningful reductions in SBP in patients with uncontrolled or resistant hypertension. Hyperkalemia emerged as the principal safety concern, whereas serious adverse events were not significantly increased. Larger and longer-term studies are needed to define long-term safety and cardiovascular outcomes.

4 November 2026 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
RPRavi Kumar Pandey
Ravi Kumar Pandey
MAMuhammad Ahmad
Muhammad Ahmad
INIqra Moatter Nurie
Iqra Moatter Nurie
ANAliya Noor
Aliya Noor
ARAli Rohan
Ali Rohan

13 November 2026 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
RPRavi Kumar Pandey
Ravi Kumar Pandey
ANAliya Noor
Aliya Noor
MAMuhammad Ahmad
Muhammad Ahmad
INIqra Moatter Nurie
Iqra Moatter Nurie
ARAli Rohan
Ali Rohan
GFGregg C. Fonarow
Gregg C. Fonarow